lifestyle.careersavvy.co.uk

Author: Moderna, Inc.

Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting

April 17, 2026
Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026

April 15, 2026
Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026

April 7, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant

March 3, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

February 27, 2026
Moderna to Present at Upcoming Conferences in March 2026

February 21, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission

February 20, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE

February 20, 2026
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates

February 20, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

February 10, 2026